New combination of Sovaldi + GS 5816 success in Hepatitis C study - Gilead
In an abstract released ahead of European Association for the Study of the Liver meeting, Gilead Sciences Inc. said once-daily HCV drug Sovaldi (sofosbuvir) plus GS-5816 for 12 weeks led to a sustained virologic response (SVR) four weeks after the end of treatment in 86-100% of HCV patients in a Phase II trial.
The trial enrolled 154 treatment-na�ve patients with HCV genotypes 1-6 infection without cirrhosis. Gilead is scheduled to present data from the trial at the European Association for the Study of the Liver meeting next month. GS-5816 is an oral pan-genotypic HCV NS5A inhibitor, and Sovaldi is a nucleotide analog HCV NS5B polymerase inhibitor.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins